tiprankstipranks
Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
US Market
ABVX
Abivax SA Sponsored ADR
RESEARCH TOOLSreports
Want to see ABVX full AI Analyst Report?

Abivax SA Sponsored ADR (ABVX) Stock Forecast & Price Target

456 Followers
See the Price Targets and Ratings of:

ABVX Analyst Ratings

Strong Buy
12Ratings
Strong Buy
11 Buy
1 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Abivax
SA Sponsored ADR
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABVX Stock 12 Month Forecast

Average Price Target

$154.18
▲(28.31% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Abivax SA Sponsored ADR in the last 3 months. The average price target is $154.18 with a high forecast of $187.00 and a low forecast of $110.00. The average price target represents a 28.31% change from the last price of $120.16.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","188":"$188","50.75":"$50.8","96.5":"$96.5","142.25":"$142.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":187,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$187.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":154.1818181818182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$154.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,50.75,96.5,142.25,188],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,129.69,134.09846153846155,138.50692307692307,142.91538461538462,147.32384615384615,151.7323076923077,156.14076923076922,160.54923076923077,164.9576923076923,169.36615384615385,173.77461538461537,178.18307692307692,182.59153846153845,{"y":187,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,129.69,131.573986013986,133.45797202797203,135.34195804195804,137.22594405594407,139.10993006993007,140.99391608391608,142.8779020979021,144.7618881118881,146.64587412587412,148.52986013986015,150.41384615384615,152.29783216783218,{"y":154.1818181818182,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,129.69,128.17538461538462,126.66076923076923,125.14615384615385,123.63153846153845,122.11692307692307,120.60230769230769,119.08769230769231,117.57307692307693,116.05846153846154,114.54384615384615,113.02923076923076,111.51461538461538,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.35,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.94,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.99,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.92,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.86,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.46,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.11,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.97,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.61,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.69,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$187.00Average Price Target$154.18Lowest Price Target$110.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on ABVX
Julian Harrison
BTIG
BTIG
$150→$175
Buy
45.64%
Upside
Assigned
06/30/26
Abivax price target raised to $175 from $150 at BTIGAbivax price target raised to $175 from $150 at BTIG
LifeSci Capital Analyst forecast on ABVX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$170
Buy
41.48%
Upside
Reiterated
06/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on ABVX
Faisal Khurshid
Jefferies
Jefferies
$108→$158
Buy
31.49%
Upside
Upgraded
06/30/26
Abivax upgraded to Buy from Hold at JefferiesAbivax upgraded to Buy from Hold at Jefferies
Barclays Analyst forecast on ABVX
Etzer Darout
Barclays
Barclays
$148
Buy
23.17%
Upside
Reiterated
06/30/26
Barclays Sticks to Its Buy Rating for Abivax SA Sponsored ADR (ABVX)
Piper Sandler Analyst forecast on ABVX
Allison Bratzel
Piper Sandler
Piper Sandler
$165
Buy
37.32%
Upside
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (NASDAQ: HTFL), Taysha Gene Therapies (NASDAQ: TSHA) and Abivax SA Sponsored ADR (NASDAQ: ABVX)
Wedbush Analyst forecast on ABVX
David Nierengarten
Wedbush
Wedbush
$90→$110
Hold
-8.46%
Downside
Reiterated
06/30/26
Abivax price target raised to $110 from $90 at WedbushAbivax price target raised to $110 from $90 at Wedbush
Truist Financial Analyst forecast on ABVX
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Abivax SA Sponsored ADR (NASDAQ: ABVX) and Larimar Therapeutics (NASDAQ: LRMR)
Guggenheim Analyst forecast on ABVX
Yatin Suneja
Guggenheim
Guggenheim
$175
Buy
45.64%
Upside
Reiterated
06/15/26
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Guggenheim
Wolfe Research Analyst forecast on ABVX
Andy Chen
Wolfe Research
Wolfe Research
$176→$136
Buy
13.18%
Upside
Assigned
06/03/26
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (NASDAQ: ABVX) and MaxCyte (NASDAQ: MXCT)
Leerink Partners Analyst forecast on ABVX
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$140
Buy
16.51%
Upside
Reiterated
06/02/26
Leerink Partners Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)
Citizens JMP Analyst forecast on ABVX
Jason Butler
Citizens JMP
Citizens JMP
$131→$187
Buy
55.63%
Upside
Reiterated
06/02/26
Abivax price target raised to $187 from $131 at CitizensAbivax price target raised to $187 from $131 at Citizens
Morgan Stanley Analyst forecast on ABVX
Judah Frommer
Morgan Stanley
Morgan Stanley
$145→$132
Buy
9.85%
Upside
Assigned
06/02/26
Abivax price target lowered to $132 from $145 at Morgan StanleyAbivax price target lowered to $132 from $145 at Morgan Stanley
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG Analyst forecast on ABVX
Julian Harrison
BTIG
BTIG
$150→$175
Buy
45.64%
Upside
Assigned
06/30/26
Abivax price target raised to $175 from $150 at BTIGAbivax price target raised to $175 from $150 at BTIG
LifeSci Capital Analyst forecast on ABVX
Sam Slutsky
LifeSci Capital
LifeSci Capital
$170
Buy
41.48%
Upside
Reiterated
06/30/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on ABVX
Faisal Khurshid
Jefferies
Jefferies
$108→$158
Buy
31.49%
Upside
Upgraded
06/30/26
Abivax upgraded to Buy from Hold at JefferiesAbivax upgraded to Buy from Hold at Jefferies
Barclays Analyst forecast on ABVX
Etzer Darout
Barclays
Barclays
$148
Buy
23.17%
Upside
Reiterated
06/30/26
Barclays Sticks to Its Buy Rating for Abivax SA Sponsored ADR (ABVX)
Piper Sandler Analyst forecast on ABVX
Allison Bratzel
Piper Sandler
Piper Sandler
$165
Buy
37.32%
Upside
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: HeartFlow, Inc. (NASDAQ: HTFL), Taysha Gene Therapies (NASDAQ: TSHA) and Abivax SA Sponsored ADR (NASDAQ: ABVX)
Wedbush Analyst forecast on ABVX
David Nierengarten
Wedbush
Wedbush
$90→$110
Hold
-8.46%
Downside
Reiterated
06/30/26
Abivax price target raised to $110 from $90 at WedbushAbivax price target raised to $110 from $90 at Wedbush
Truist Financial Analyst forecast on ABVX
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Abivax SA Sponsored ADR (NASDAQ: ABVX) and Larimar Therapeutics (NASDAQ: LRMR)
Guggenheim Analyst forecast on ABVX
Yatin Suneja
Guggenheim
Guggenheim
$175
Buy
45.64%
Upside
Reiterated
06/15/26
Abivax SA Sponsored ADR (ABVX) Gets a Buy from Guggenheim
Wolfe Research Analyst forecast on ABVX
Andy Chen
Wolfe Research
Wolfe Research
$176→$136
Buy
13.18%
Upside
Assigned
06/03/26
Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (NASDAQ: ABVX) and MaxCyte (NASDAQ: MXCT)
Leerink Partners Analyst forecast on ABVX
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$140
Buy
16.51%
Upside
Reiterated
06/02/26
Leerink Partners Sticks to Their Buy Rating for Abivax SA Sponsored ADR (ABVX)
Citizens JMP Analyst forecast on ABVX
Jason Butler
Citizens JMP
Citizens JMP
$131→$187
Buy
55.63%
Upside
Reiterated
06/02/26
Abivax price target raised to $187 from $131 at CitizensAbivax price target raised to $187 from $131 at Citizens
Morgan Stanley Analyst forecast on ABVX
Judah Frommer
Morgan Stanley
Morgan Stanley
$145→$132
Buy
9.85%
Upside
Assigned
06/02/26
Abivax price target lowered to $132 from $145 at Morgan StanleyAbivax price target lowered to $132 from $145 at Morgan Stanley
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Abivax SA Sponsored ADR

3 Months
Thomas SmithLeerink Partners
Success Rate
7/13 ratings generated profit
54%
Average Return
+124.04%
Copying Thomas Smith's trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +124.04% per trade.
1 Year
Thomas SmithLeerink Partners
Success Rate
8/13 ratings generated profit
62%
Average Return
+336.54%
Copying Thomas Smith's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +336.54% per trade.
2 Years
Thomas SmithLeerink Partners
Success Rate
13/13 ratings generated profit
100%
Average Return
+647.05%
Copying Thomas Smith's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +647.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABVX Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
2
2
2
18
Buy
18
19
14
18
15
Hold
0
0
0
0
3
Sell
1
1
1
2
2
Strong Sell
0
0
0
0
0
total
20
22
17
22
38
In the current month, ABVX has received 33 Buy Ratings, 3 Hold Ratings, and 2 Sell Ratings. ABVX average Analyst price target in the past 3 months is 154.18.
Each month's total comprises the sum of three months' worth of ratings.

ABVX Financial Forecast

ABVX Earnings Forecast

Next quarter’s earnings estimate for ABVX is -$0.82 with a range of -$1.42 to -$0.56. The previous quarter’s EPS was -$0.71. ABVX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ABVX has Performed in-line its overall industry.
Next quarter’s earnings estimate for ABVX is -$0.82 with a range of -$1.42 to -$0.56. The previous quarter’s EPS was -$0.71. ABVX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ABVX has Performed in-line its overall industry.
No data currently available

ABVX Sales Forecast

Next quarter’s sales forecast for ABVX is $783.00K with a range of $0.00 to $1.89M. The previous quarter’s sales results were $0.00. ABVX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ABVX has Performed in-line its overall industry.
Next quarter’s sales forecast for ABVX is $783.00K with a range of $0.00 to $1.89M. The previous quarter’s sales results were $0.00. ABVX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ABVX has Performed in-line its overall industry.

ABVX Stock Forecast FAQ

What is ABVX’s average 12-month price target, according to analysts?
Based on analyst ratings, Abivax SA Sponsored ADR’s 12-month average price target is 154.18.
    What is ABVX’s upside potential, based on the analysts’ average price target?
    Abivax SA Sponsored ADR has 28.31% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ABVX a Buy, Sell or Hold?
          Abivax SA Sponsored ADR has a consensus rating of Strong Buy which is based on 11 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Abivax SA Sponsored ADR’s price target?
            The average price target for Abivax SA Sponsored ADR is 154.18. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $187.00 ,the lowest forecast is $110.00. The average price target represents 28.31% Increase from the current price of $120.16.
              What do analysts say about Abivax SA Sponsored ADR?
              Abivax SA Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of ABVX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.